← 返回

用于同基因小鼠肿瘤模型的可追踪 CAR-T 细胞生成方案

英文原题:Protocol to generate traceable CAR T cells for syngeneic mouse cancer models.

查看英文原题

Protocol to generate traceable CAR T cells for syngeneic mouse cancer models.

PubMed 2024/02/16(内容时间) STAR Protoc Q4 · IF 1.4(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

嵌合抗原受体(CAR)T细胞免疫疗法的疗效受到免疫抑制性肿瘤微环境导致的T细胞浸润和活化不足的限制。在免疫健全的小鼠癌症模型中使用优化的小鼠CAR-T 细胞进行临床前研究,将有助于阐明免疫治疗耐药的潜在机制。在此,我们介绍一种制备小鼠T细胞并生成CAR-T 细胞的方案。随后,我们详细描述在同基因小鼠胶质瘤模型中测试其治疗效果并追踪这些细胞的步骤。关于本方案使用和执行的完整细节,请参阅Zhang等。1。

展开英文摘要原文

The efficacy of chimeric antigen receptor (CAR) T cell immunotherapy is limited by insufficient infiltration and activation of T cells due to the immunosuppressive tumor microenvironment. Preclinical studies with optimized mouse CAR T cells in immunocompetent mouse cancer models will help define the mechanisms underlying immunotherapy resistance.

Here, we present a protocol for preparing mouse T cells and generating CAR T cells.

We then detail procedures for testing their therapeutic efficacy and tracking them in a syngeneic mouse glioma model. For complete details on the use and execution of this protocol, please refer to Zhang et al. 1 .

论文信息

作者
Zhang D、Krimitza E、Han K、Su R、Xu DJ、Xu JR、Gong Y、Fan Y
第一作者单位
Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: duozhang@pennmedicine.upenn.edu.United States
通讯作者单位
Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: fanyi@upenn.edu.United States
文献类型
非美国政府资助研究 · 美国 NIH 资助研究
期刊
STAR protocols2024 Mar 15
原文标识
PubMed 38367235 · DOI 10.1016/j.xpro.2024.102898